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Vascular endothelial growth factor is a secreted glycoprotein that acts on endothelial cells
to induce developmental and physiological angiogenesis. It has also been implicated in
angiogenesis occurring in several pathologies, most notably, cancer. Alternative splicing
of VEGF mRNA transcripts results in several isoforms with distinct properties depending
on their exon composition. Recently, a new isoform has been identified, VEGF111 with
a unique exon composition responsible for its high angiogenic potential. In humans,
the only known inducer of VEGF111 is DNA damage but its natural presence in the
uterus of the viviparous lizard, Saiphos equalis, suggests other mechanisms of regulation.
Most interestingly, the possible relationship between the evolution of viviparity and the
associated increased risk in developing cancer may be important in understanding the
mechanisms underlying tumor development.
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INTRODUCTION
Angiogenesis is a crucial process during tumor growth, inva-
sion and metastasis for the rapid development and maintenance
of a blood supply to developing tumors (Weidner et al., 1991).
Capillaries do not usually actively proliferate under normal con-
ditions in adults, but tumors secrete several growth factors to
stimulate surrounding endothelial cells (ECs) to invade, rapidly
proliferate and develop a dedicated blood supply (Carmeliet and
Jain, 2000).
One of the most important growth factors involved in angio-
genesis is vascular endothelial growth factor (VEGF), a major
mitogen that acts selectively on ECs to stimulate angiogenesis
(Ferrara and Henzel, 1989; Keck et al., 1989). Also referred to as
VEGF-A, vascular permeability factor and vasculotropin, VEGF
belongs to a family of proteins along with VEGF-B, C, D and
placenta growth factor (Ferrara, 2004).
VEGF is widely expressed in human fetal and adult organs, pri-
marily in lung, kidney and spleen, and at lower concentrations
in several other major organs. It is vital for both maintenance
of the vasculature and stimulation of angiogenesis (Shifren et al.,
1994). Cancers have developed strategies to utilize the angiogenic
role of VEGF to grow and metastasize, but this rapid and uncon-
trolled angiogenesis results in the blood vessels within tumors
often having abnormal characteristics including tortuosity, ran-
dom branching and variable lumen size (Gimbrone et al., 1972;
Langenkamp and Molema, 2009). A newly discovered splice vari-
ant of VEGF, known as VEGF111, is produced by human cells
with DNA damage and potentially supports the development and
metastasis of tumors due to its high angiogenic activity (Mineur
et al., 2007) and may provide new insights into how cancers
develop.
BACKGROUND TO A NEW ISOFORM: BIOLOGICAL EFFECTS
OF VEGF
VEGF induces angiogenesis by selectively binding to two tyrosine
kinase receptors, VEGFR-1 and VEGFR-2, as well as the neu-
ropilin co-receptor, expressed on the surface of ECs (De-Vries
et al., 1992; Terman et al., 1992). Both receptors are essential for
normal vascular development, but VEGFR-2 is the major regu-
lator of the biological effects of VEGF via downstream pathways
(Shalaby et al., 1995; Olsson et al., 2006) (Figure 1). ECs within
tumors are often hypoxic, which induces the overexpression of
both VEGFR-1 and 2 on these ECs, contributing to uncontrolled
angiogenesis (Veikkola et al., 2000).
EC activation by VEGF induces the production of several
proteins, including interstitial collagenase, and urokinase-type
and tissue-type plasminogen activators, to facilitate EC invasion
into the underlying basement membrane and extracellular matrix
(Pepper et al., 1991; Unemori et al., 1992). There is also an
increase in vascular permeability (Senger et al., 1983), leading to
the extravasation of proteins into the surrounding tissue due to
opening intercellular junctions and production of fenestrations
between ECs. Tumors exhibit uncontrolled vascular permeability
due to the increased incidence of these fenestrations (Roberts and
Palade, 1995).
VEGF GENE AND ISOFORMS
The gene for VEGF encodes 8 exons and 7 introns. Exons 1 and
2 encode for the signal peptide and exons 3 and 4 encode for
the binding sites to VEGFR-1 and 2 respectively (Robinson and
Stringer, 2001). The other exons may or may not be present,
resulting in various isoforms. Exon splicing of the mRNA tran-
script results in four naturally expressed isoforms named after the
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FIGURE 1 | Signaling pathways of VEGFR-2. The binding of VEGF to
VEGFR-2 results in the activation of several intracellular molecules to
induce cell survival, increase vascular permeability, cellular migration and
proliferation.
number of amino acids encoded after signal sequence cleavage
(Ferrara, 2004) (Figure 2).
The residues encoded by exons 6 and 7 contain heparin and
neuropilin-binding sites, limiting the ability of VEGF189 and
VEGF206, and to a lesser degree VEGF165, to diffuse freely upon
secretion, resulting in a high proportion remaining bound to the
cell surface or surrounding extracellular matrix (Leung et al.,
1989). In contrast, VEGF121 lacks these binding domains mak-
ing it freely diffusible (Houck et al., 1992). Whereas VEGF165,
VEGF121, and VEGF189 are widely expressed in a range of nor-
mal and pathological tissues, VEGF206 is rare and has only been
identified in the cDNA library of human fetal liver (Houck et al.,
1991). Other isoforms have been identified in transformed cells
but most recently, the discovery of the VEGF111 isoform has
raised questions about its involvement in tumor development and
metastasis (Mineur et al., 2007).
THE NEW ISOFORM: VEGF111 DISCOVERY AND
IDENTIFICATION
VEGF111 is encoded by exons 1–4 and 8 (Figure 2) and is induced
by DNA damage to human cells caused by ultraviolet B (UV-B)
radiation and genotoxic drugs (Mineur et al., 2007) as well as mild
hypothermia (Neutelings et al., 2013). The total VEGF mRNA
levels are not increased, but rather the proportions of the other
VEGF isoforms are altered to accommodate VEGF111 produc-
tion. This is primarily at the expense of VEGF165 (Mineur et al.,
2007). The concentration of VEGF111 also increases with increas-
ing UV-B intensity, presumably because there is a higher rate of
genetic damage occurring, in this case the formation of pyrim-
idine dimers. Genotoxic agents that result in genetic damage
through double strand breaks, including captothecin, mimosin
and mitomycin C, also induce VEGF111 formation.
The only documented evidence of the natural expression of
VEGF111 is in the uterine wall, testes and kidneys of Saiphos
equalis, a viviparous lizard from eastern Australia. VEGF111 is
absent from any other somatic organ tested (Murphy et al., 2010).
Uterine expression of VEGF111 increases during pregnancy in
S. equalis. Other isoforms involved in uterine angiogenesis are
also expressed within the uterus. Important changes occur in
uterine microvascular architecture in S. equalis to support the
developing embryo, with increased vessel density evident partic-
ularly in late stage pregnancy (Parker et al., 2010). No VEGF111
mRNA transcripts have yet been identified in any other species
(Murphy et al., 2010).
The role of VEGF111 in the uterus of S. equalis is currently
unknown, but may be involved in the rapid angiogenesis of
both the uterus and chorioallantoic membrane of the embryo
(Murphy et al., 2010). The significance of the natural production
of VEGF111 in S. equalis suggests there are means of regulating its
production, other than genetic damage. VEGF111 may be under
hormonal regulation, possibly by estrogen or progesterone, but
the exact nature of VEGF111 regulation is unknown.
PROPERTIES OF VEGF111
VEGF111 is angiogenic and will induce vascularization in vivo and
in vitro (Mineur et al., 2007) resulting in the formation of a func-
tional vasculature (Delcombel et al., 2013). VEGF111 is unique
in that it is resistant to proteolytic cleavage and retains its com-
plete biological activity upon exposure to plasmin, due to not
encoding for exon 5, which contains the residues Arg110-Ala111,
the site of plasmin cleavage (Keyt et al., 1996). All other iso-
forms encode for this cleavage site and their biological activity
is decreased upon exposure to plasmin (Houck et al., 1992). Like
VEGF121, VEGF111 lacks extracellular matrix binding regions and
thus is also freely diffusible (Mineur et al., 2007), which is evident
from the widespread vascular permeability induced by VEGF111
in comparison to VEGF165 (Delcombel et al., 2013). These unique
characteristics result in its high angiogenic activity compared to
other VEGF isoforms as shown by the ability of VEGF111 to pro-
mote early blood vessel recruitment and reduce the effects of
ischemia and hypoxia in newly grafted tissue (Labied et al., 2013)
and improve healing in tendon injuries (Kaux et al., 2014) com-
pared to other isoforms. The high angiogenic activity, and the fact
that it is induced by genetic damage, allows VEGF111 to support
the development of a blood supply to tumors (Mineur et al., 2007;
Delcombel et al., 2013).
VEGF111 is fully glycosylated, unlike VEGF165 and VEGF121,
which are only partially glycosylated. Glycosylation is impor-
tant in efficient protein secretion, which occurs with VEGF111,
but does not affect its biological activity (Mineur et al., 2007).
VEGF111 also stimulates the migration of ECs but not monocytes.
As monocyte chemotaxis is primarily mediated via VEGFR-1,
the chemotactic signals stimulated by VEGF111 are primarily
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FIGURE 2 | Exon composition of various VEGF isoforms. Exon composition
of the four naturally expressed isoforms of VEGF in humans. Exons 6 and 7
encode for heparin and neuropilin binding sites. Note the 24 amino acid
insertion within VEGF189 making up exon 6a, and also the same 24 amino acid
insertion followed by a 17 amino acid insertion (exon 6b) in VEGF206. The exon
composition of the VEGF111 isoform is also included for comparison.
mediated via VEGFR-2 (Mineur et al., 2007). VEGF111 binds to
VEGFR-2 with similar affinity to the other isoforms and along
with VEGF121, is the strongest inducer of VEGFR-2 phospho-
rylation in the absence of the neuropilin co-receptor, which is
needed for complete activation by VEGF165 (Delcombel et al.,
2013). VEGF111 is unable to bind this neuropilin co-receptor due
to lacking the important binding domains, but the lack of bind-
ing has no impact on its biological activity (Delcombel et al.,
2013).
While hypoxia and hypoglycemia induce VEGF expression
by increasing the stability of the mRNA transcript (Stein et al.,
1995), mammalian cells do not produce VEGF111 in these condi-
tions. Apoptosis and reactive oxygen species also do not induce
VEGF111 expression (Mineur et al., 2007). While inducers of
VEGF111 expression remain unclear, caffeine, epigallocatechin
gallate (an antioxidant extracted from tea) and resveratrol (a
phenol produced by some plants) inhibit VEGF111 production
(Munaut et al., 2010). Thus, the only known inducer of VEGF111
in human cells is genetic damage (Mineur et al., 2007; Neutelings
et al., 2013).
ROLE OF VEGF IN CANCER
Angiogenesis is critical in the growth of solid tumors, as a tumor
cannot grow beyond a size of 2mm without its own vascular sup-
port (Gimbrone et al., 1972). VEGFmRNA is expressed in several
types of tumors and inhibiting VEGF inhibits tumor growth
in vivo, indicating its importance in tumor angiogenesis. Several
anti-VEGF therapies have been developed as cancer treatments,
some showing success in improving survival rates (review by Jain
et al., 2006).
An issue that has recently emerged is the detrimental effects of
VEGF inhibitors on treatment progression, particularly regard-
ing increased malignancy and metastasis (Paez-Ribes et al.,
2009). The normalization of the vessels, which involves block-
ing VEGF signaling to repair vascular abnormalities, may be a
better treatment option than eliminating the tumor vasculature,
reducing metastasis and improving chemotherapeutic treatments
(Mazzone et al., 2009).
Genetic mutations, such as those caused by UV-B radiation
and genotoxic drugs, are a major cause of cancer, resulting in
abnormal cellular functions (Brash et al., 1991). Thus, it is pos-
sible that cancers induced by genotoxic actions may produce
VEGF111. Genotoxic drugs such as campothecin and mitomycin
C, both of which induce VEGF111 production, are common
chemotherapeutics, and thus it is possible that the production of
VEGF111 during cancer therapy increases drug resistance (Mineur
et al., 2007). Therefore, examining the role of VEGF111 in angio-
genesis and EC activation may provide a significant contribution
to understanding this process.
When nude mice are injected with cells expressing equal con-
centrations of different VEGF isoforms, the vascular structures
differ. Tumors expressing VEGF111 are poorly vascularized in
comparison to tumors expressing other isoforms. However, the
vessel density in the surrounding tissue is highest in the VEGF111
tumors compared to all other isoforms tested, which have sig-
nificantly lower vessel density (Mineur et al., 2007; Delcombel
et al., 2013). This result stems from the ability of VEGF111 to
freely diffuse from its point of secretion because it is not restricted
by extracellular matrix binding. VEGF111 has a longer half-life
compared to VEGF165 and so its actions remain active for longer
(Mineur et al., 2007). Thus, a tumor with the ability to secrete sev-
eral different isoforms, including VEGF111, would result in both
a highly vascularized tumor and surrounding tissue, potentially
increasing the ability to metastasize.
Other VEGF isoforms have been identified in transformed cells
including VEGF145 (Poltorak et al., 1997) and VEGF162 (Lange
et al., 2003). VEGF145 lacks exons 6b and 7, and is secreted pri-
marily from cancer cell lines derived from the female reproductive
system (Poltorak et al., 1997), whereas VEGF162 only lacks exon
7 and is secreted by ovarian carcinoma cells (Lange et al., 2003).
Both isoforms are angiogenic and will induce angiogenesis in vitro
and in vivo and their biological activity is similar to the other iso-
forms (Lange et al., 2003). The distinct difference to VEGF111
however, is that they still encode the site of plasmin cleavage,
and thus lose their biological activity upon exposure to plas-
min. Further investigation in mammalian cancers is necessary,
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however the presence of VEGF111 primarily in reproductive tis-
sues of S. equalis raises questions whether this isoform may also
be present in human reproductive tract cancers.
SIMILARITIES OF CANCER TO INVASIVE PLACENTATION
There are similar molecular mechanisms between how tumors
invade and metastasize compared to the trophoblastic invasion
in hemochorial placentation that occurs in humans, particularly
regarding angiogenesis (Murray and Lessey, 1999; Hayakawa,
2006). It has been proposed that there is a positive correla-
tion between the degree of placental invasiveness and the ability
of metastatic tumors to develop (D’Souza and Wagner, 2014).
Mammals that have evolved to develop the less invasive epithe-
liochorial and endotheliochorial placentas have a lower observed
rate of cancer malignancies. In less invasive forms of placentation,
the maternal endometrium limits the invasion of the trophoblast
cells, and it is hypothesized that this may correlate with a global
suppression of tumor metastasis (Priester and Mantel, 1971;
D’Souza and Wagner, 2014).
The discovery of VEGF111 as both a potential stimulator
of angiogenesis in mammalian tumors (Mineur et al., 2007;
Delcombel et al., 2013) and in the uterus of S. equalis during
pregnancy (Murphy et al., 2010) further supports a connection
between placentation and cancer. The fact that S. equalis is transi-
tioning between egg laying and giving live birth with a placenta
(Stewart et al., 2000) also suggests that this evolutionary pro-
cess could contribute to an increased susceptibility to cancer.
Therefore, an understanding into the role of VEGF111 in EC
biology may lead to a better understanding of this susceptibility.
VEGF111 AS A POTENTIAL THERAPEUTIC AGENT
The high angiogenic activity of VEGF111 could also be used as a
potential therapeutic agent to increase vascularization in ischemic
diseases and lesions. The presence of plasmin in chronic wounds
results in rapid VEGF cleavage (Lauer et al., 2000), but the ability
of VEGF111 to resist this degradation has recently been exploited
to improve ischemia and wound healing (Labied et al., 2013; Kaux
et al., 2014). This resistance, as well being freely diffusible, allows
VEGF111 to induce rapid angiogenesis and rapid EC prolifera-
tion compared to the other isoforms, which results in the earlier
formation of a functional vasculature and blood supply to the
ischemic region (Labied et al., 2013). Further investigation into
the clinical applications of VEGF111 is necessary, but the initial
data are promising.
CONCLUSION
VEGF plays a crucial role in normal developmental and embry-
ological angiogenesis as well as contributing to the progression of
several pathological conditions. The discovery of VEGF111 is an
important advance in understanding the mechanisms by which
tumors develop their dedicated blood supply and is critical in
their ability to grow and metastasize rapidly. While there are sev-
eral isoforms of VEGF, VEGF111 is the only isoform to resist
proteolytic degradation and may provide further insights into
the pathogenesis and treatment of diseases that are dependent on
angiogenesis. Future work on this molecule should be directed at
understanding the mechanisms underlying angiogenesis and has
great promise in developing new therapeutics to target tumori-
genesis and to treat ischemic diseases. This should involve exam-
ining the actions of VEGF111 on EC biology and its capacity to
facilitate the formation of functional vessels in several models to
specifically address its role in angiogenesis. This should encom-
pass its actions in cancer, both as a potential contributor to
metastasis during disease progression, and drug resistance dur-
ing disease treatment. Further investigation should also expand
on the previous work that focused on VEGF111 as a therapeutic
agent. Its presence in the uterus of pregnant lizards provides a
unique way to understand those mechanisms.
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